MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung ...

MannKind Corporation (MNKD) said on Wednesday that it has entered into up to $500 million strategic financing agreement with ...

Westlake Village-based MannKind Corporation is receiving some extra help to advance some of its short and long-term growth strategies. Announced Aug. 6, MannKind, a biotech company focused on inhaled ...

MannKind Corporation ( MNKD) has disclosed a new risk, in the Capital Markets category. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...

MannKind Corporation (NASDAQ:MNKD) is one of the penny stocks that will skyrocket. On July 16, H.C. Wainwright assumed ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good morning, and welcome to the MannKind Corporation Second ...

MannKind Corporation (NASDAQ: MNKD) is a company that is poised for major growth in the biopharmaceutical sector, particularly in the development and commercialization of inhaled therapeutic ...

MannKind Corporation announced significant growth in its financial performance for the year and fourth quarter ending December 31, 2024, reporting total revenues of $286 million, a 43% increase ...

MannKind Corp (NASDAQ:MNKD) is set to release its Q2 2025 earnings on Aug 6, 2025. The consensus estimate for Q2 2025 revenue ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), will release its 2024 fourth quarter and full year financial results after ...

MannKind saw decent growth from its two core products in Q2 and just signed a new non-dilutive financing agreement with ...

The big shareholder groups in MannKind Corporation (NASDAQ:MNKD) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a ...